Do I Qualify for the Depo-Provera Brain Tumor Lawsuit?

Depo provera meningioma lawsuit eligibility requirements are the first thing many women ask about after learning that this common birth control shot may cause brain tumors. Nearly 3,800 lawsuits are now pending in federal court against Pfizer. In December 2025, the FDA finally added a meningioma warning to the Depo-Provera label. However, European and Canadian regulators had already required that same warning three years earlier.

A major 2024 study in the British Medical Journal found that women who used injectable medroxyprogesterone acetate — the active ingredient in Depo-Provera — had 5.55 times higher odds of developing an intracranial meningioma. Understanding depo provera meningioma lawsuit eligibility requirements can help you determine whether you have a valid legal claim. The first bellwether trial is scheduled for December 2026.

What Is a Meningioma and Why Is Depo-Provera Linked to It?

A meningioma is a tumor that grows on the membranes surrounding the brain and spinal cord. Most meningiomas are classified as benign. However, even benign brain tumors can cause serious symptoms. These include chronic headaches, vision problems, seizures, and cognitive difficulties. In many cases, surgery is required to remove the tumor.

Scientists first identified high concentrations of progesterone receptors in meningioma cells back in 1983. Depo-Provera delivers a large dose of synthetic progesterone every three months. Plaintiffs allege that Pfizer knew about this biological connection for decades. As a result, the core legal theory is that Pfizer failed to warn patients and doctors about the meningioma risk. Depo provera meningioma lawsuit eligibility requirements center on this failure-to-warn claim.

Depo Provera Meningioma Lawsuit Eligibility Requirements Explained

To qualify for a Depo-Provera meningioma lawsuit, you typically must meet several criteria. The following table breaks down the standard requirements used in MDL 3140, the federal multidistrict litigation overseen by Judge M. Casey Rodgers in the Northern District of Florida.

Documentation is important when evaluating depo provera meningioma lawsuit eligibility requirements. You will need pharmacy records confirming your injection history. You will also need MRI or CT imaging reports showing the meningioma diagnosis. For example, your doctor’s clinical notes linking the timeline of use and diagnosis can strengthen your claim significantly.

In most cases, women who received only a single injection do not meet the depo provera meningioma lawsuit eligibility requirements. The scientific evidence and legal filings focus on repeated, long-term exposure to medroxyprogesterone acetate. Typically, attorneys look for at least one year of continuous use.

Statute of Limitations and Filing Deadlines

Every state has its own statute of limitations for product liability claims. These deadlines range from 1 to 6 years, depending on where you live. Most states allow 2 to 3 years. However, the clock does not always start on your last injection. Most states follow the “discovery rule.” This means the deadline starts when you knew or should have known that Depo-Provera may have caused your meningioma.

Two key dates often serve as discovery triggers. The first is March 2024, when the BMJ study was published. The second is December 2025, when the FDA officially added the meningioma warning. Some states also apply a statute of repose — an absolute deadline measured from the date of last product use. As a result, depo provera meningioma lawsuit eligibility requirements include filing before your state’s deadline expires. If Pfizer is found to have concealed risk data, the fraudulent concealment doctrine may pause the clock in certain states.

Meeting the depo provera meningioma lawsuit eligibility requirements is time-sensitive. Women in states with shorter deadlines should consult an attorney as soon as possible. Waiting too long could bar your claim entirely.

What Happens Next in the Litigation

The Depo-Provera MDL has grown quickly. As of May 2026, approximately 3,769 cases are consolidated before Judge Rodgers. Critical Daubert hearings are scheduled for June 24–26, 2026. These hearings will determine whether plaintiffs’ scientific experts can testify that Depo-Provera causes meningioma. If the experts survive this challenge, the first bellwether trial — Blonski v. Pfizer — is set to begin on December 7, 2026.

No global settlement has been reached yet. However, bellwether trial outcomes typically drive settlement negotiations in mass tort cases. Pre-trial estimates suggest individual case values could range from $75,000 to over $1,000,000. Cases involving brain surgery are expected to fall in the highest settlement tier. Depo provera meningioma lawsuit eligibility requirements remain the same whether the case settles or goes to trial.

If you believe you meet the depo provera meningioma lawsuit eligibility requirements, gathering your medical records now is a smart first step. Request your pharmacy injection history and all brain imaging reports. These documents form the foundation of any potential claim.

Frequently Asked Questions

How many Depo-Provera injections do I need to have received to qualify?

In most cases, attorneys require at least four injections, or roughly one year of use. However, some firms evaluate claims with as few as two injections. The depo provera meningioma lawsuit eligibility requirements generally focus on prolonged, repeated exposure to the drug.

What if my meningioma was diagnosed as benign — can I still file?

Yes. Both benign and malignant meningiomas qualify under the depo provera meningioma lawsuit eligibility requirements. Even benign meningiomas can require surgery and cause lasting neurological damage. For example, many plaintiffs in MDL 3140 were diagnosed with benign tumors that still required invasive treatment.

Is there a deadline to file a Depo-Provera lawsuit?

Yes. Statutes of limitations vary by state, typically ranging from 1 to 6 years. The discovery rule may extend your deadline if you only recently learned about the connection between Depo-Provera and meningioma. However, depo provera meningioma lawsuit eligibility requirements include filing within your state’s time limit. Consulting an attorney promptly is strongly recommended.

Who is the defendant in these lawsuits?

The primary defendant is Pfizer Inc., which holds the drug’s New Drug Application. Pharmacia & Upjohn Co. LLC, a Pfizer subsidiary and the original developer, is also named. Additionally, several generic manufacturers including Greenstone LLC and Prasco Laboratories are defendants in some cases.

Check If You Qualify

You may be eligible for compensation from an active lawsuit and not even know it. Use our free tools to find out.

Official Sources & Resources

For verified mass tort and legal information:

• JPML (Case Data): jpml.uscourts.gov
• U.S. Department of Justice: justice.gov
• Cornell Law Institute: law.cornell.edu
• NCSL (State Laws): ncsl.org
• FDA Recalls & Safety: fda.gov

Content last reviewed May 2026. If you notice any outdated information, please contact us.

Related Guides

• Complete Mass Tort Guide
• All Active MDL Cases
• State Tort Reform Laws
• Eligibility Quiz Tool
• Damage Cap Lookup Tool

Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content. Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.